First metabolic profile of XLR-11, a novel synthetic cannabinoid, obtained by using human hepatocytes and high-resolution mass spectrometry
about
Approaches, Challenges, and Advances in Metabolism of New Synthetic Cannabinoids and Identification of Optimal Urinary Marker Metabolites.Metabolites of 5F-AKB-48, a synthetic cannabinoid receptor agonist, identified in human urine and liver microsomal preparations using liquid chromatography high-resolution mass spectrometry.Pentylindole/Pentylindazole Synthetic Cannabinoids and Their 5-Fluoro Analogs Produce Different Primary Metabolites: Metabolite Profiling for AB-PINACA and 5F-AB-PINACAIdentification of AB-FUBINACA metabolites in authentic urine samples suitable as urinary markers of drug intake using liquid chromatography quadrupole tandem time of flight mass spectrometry.High-resolution mass spectrometric metabolite profiling of a novel synthetic designer drug, N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide (STS-135), using cryopreserved human hepatocytes and assessment of metabolic stability with humMetabolic profiling of new synthetic cannabinoids AMB and 5F-AMB by human hepatocyte and liver microsome incubations and high-resolution mass spectrometry.Using cheminformatics to predict cross reactivity of "designer drugs" to their currently available immunoassays.Quantitative urine confirmatory testing for synthetic cannabinoids in randomly collected urine specimens.Nontargeted SWATH acquisition for identifying 47 synthetic cannabinoid metabolites in human urine by liquid chromatography-high-resolution tandem mass spectrometry.Assessment of tandem mass spectrometry and high-resolution mass spectrometry for the analysis of bupivacaine in plasma.Metabolism of RCS-8, a synthetic cannabinoid with cyclohexyl structure, in human hepatocytes by high-resolution MS.Current applications of high-resolution mass spectrometry for the analysis of new psychoactive substances: a critical review.In Vitro and In Vivo Human Metabolism of Synthetic Cannabinoids FDU-PB-22 and FUB-PB-22.Quantification of [1-(5-fluoropentyl)-1H-indol-3-yl](naphthalene-1-yl)methanone (AM-2201) and 13 metabolites in human and rat plasma by liquid chromatography-tandem mass spectrometry.Genotoxic properties of XLR-11, a widely consumed synthetic cannabinoid, and of the benzoyl indole RCS-4.Recent developments in urinalysis of metabolites of new psychoactive substances using LC-MS.Synthetic cannabinoids pharmacokinetics and detection methods in biological matrices.Kinetic and metabolic profiles of synthetic cannabinoids NNEI and MN-18.High-resolution mass spectrometry in toxicology: current status and future perspectives.Detection of the recently emerged synthetic cannabinoid 5F-MDMB-PICA in 'legal high' products and human urine samples.Detection of main metabolites of XLR-11 and its thermal degradation product in human hepatoma HepaRG cells and human urine.Synthetic cannabinoids and acute kidney injury.Analysis of Parent Synthetic Cannabinoids in Blood and Urinary Metabolites by Liquid Chromatography Tandem Mass Spectrometry.Metabolism of synthetic cannabinoids PB-22 and its 5-fluoro analog, 5F-PB-22, by human hepatocyte incubation and high-resolution mass spectrometry.Study on the phase I metabolism of novel synthetic cannabinoids, APICA and its fluorinated analogue.Identification of AKB-48 and 5F-AKB-48 Metabolites in Authentic Human Urine Samples Using Human Liver Microsomes and Time of Flight Mass Spectrometry.Synthetic cannabimimetic agents metabolized by carboxylesterases.Metabolic fate of desomorphine elucidated using rat urine, pooled human liver preparations, and human hepatocyte cultures as well as its detectability using standard urine screening approaches.LC-QTOF-MS as a superior strategy to immunoassay for the comprehensive analysis of synthetic cannabinoids in urine.Metabolic characterization of (1-(5-fluoropentyl)-1H-indol-3-yl)(4-methyl-1-naphthalenyl)-methanone (MAM-2201) using human liver microsomes and cDNA-overexpressed cytochrome P450 enzymes.Toxicokinetics of new psychoactive substances: plasma protein binding, metabolic stability, and human phase I metabolism of the synthetic cannabinoid WIN 55,212-2 studied using in vitro tools and LC-HR-MS/MS.Determination of urinary metabolites of XLR-11 by liquid chromatography-quadrupole time-of-flight mass spectrometry.In vitro and in vivo human metabolism of the synthetic cannabinoid AB-CHMINACA.Cytochrome P450-mediated metabolism of the synthetic cannabinoids UR-144 and XLR-11
P2860
Q30244676-12C6D1ED-6599-4A81-BBA1-FD01CB0BBE05Q34419089-E87884F6-AF54-427B-B731-7F49E9B69074Q34464722-694C13E5-F1E0-4A8F-93B1-2C80A0F5EE3CQ34501432-6D19DF50-3A0F-49A1-9B39-9C3872091162Q34514221-0DD060E7-955C-4240-959D-1B393D582592Q34519359-5D4871FC-BA3F-49B3-8262-623180300703Q35172366-211C5A94-78F8-4167-A5A0-88C6A6C70C9FQ35187100-32754D07-B436-4DC9-9C0B-EA74875B2867Q35254099-A8EDF277-3EC9-41A0-9B39-4C829C77DAD2Q35627328-F6FF09BC-F4E4-4A3D-A159-8B502EF5D0EEQ35748441-22AF85C8-296F-4B44-9BCA-518977BBB162Q36410928-A346DA6D-3259-46B4-8A6E-96A9CF1FDAABQ36653901-D8B65FDD-B4B1-4FAC-98BF-16A5199EA9E9Q36950560-4D960A3C-FCDB-46CD-9821-AEEEF8A04589Q37408099-D8F29109-AC8C-4DDC-87EC-EE17EEE70B28Q38260819-1063D27E-D64B-4062-ABAF-1DADBBE8DEE9Q38411456-70A8E1D5-4C50-4FAF-9EC2-C04A41272784Q38611708-D11E90A1-7B2E-4235-8316-42E660E417A8Q38846184-E496F18A-8F10-4F57-A881-53864ACB8F58Q38858777-9E3C2ED9-7E53-4B2D-8943-A24A2700EF75Q38918740-F2E6A9AE-789A-4EA4-A25C-D9F507F1396DQ41766626-9CED2D60-F11F-4B8B-8A76-268404C82B8FQ42751412-5288D41B-1B08-4431-92F9-77DD46065F77Q45898212-B402F270-74D1-4148-9E06-D3257D5218E5Q46809828-C0D6DFFD-FC4B-409B-8744-D79072FD1864Q50277873-5BE9F8D5-2035-485F-BD69-2259E4A3C313Q50616345-FC1269CB-AFC1-461E-A193-3971AA31E01FQ51271242-759899ED-EFAE-4E46-9B88-A55A58B78E0EQ51758609-46C585BB-2548-4864-B12E-BC0FE36A81EDQ52815923-6CA5939C-8BA2-4754-B5E5-820215161C4EQ52887320-EF666737-3A4B-4AE2-BACD-F0A246A3EECBQ53188520-B87D58A9-AB91-49E0-AA5E-321DD6427CD2Q53546061-5EBE394B-56B0-4A2A-ADB1-7D8C63FBF402Q57814871-70FCA951-E00C-4BC7-9A2D-877932ABEA1C
P2860
First metabolic profile of XLR-11, a novel synthetic cannabinoid, obtained by using human hepatocytes and high-resolution mass spectrometry
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
First metabolic profile of XLR ...... h-resolution mass spectrometry
@ast
First metabolic profile of XLR ...... h-resolution mass spectrometry
@en
type
label
First metabolic profile of XLR ...... h-resolution mass spectrometry
@ast
First metabolic profile of XLR ...... h-resolution mass spectrometry
@en
prefLabel
First metabolic profile of XLR ...... h-resolution mass spectrometry
@ast
First metabolic profile of XLR ...... h-resolution mass spectrometry
@en
P2093
P2860
P1433
P1476
First metabolic profile of XLR ...... h-resolution mass spectrometry
@en
P2093
Adarsh S Gandhi
Ariane Wohlfarth
Hua-fen Liu
Karl B Scheidweiler
Mingshe Zhu
Shaokun Pang
P2860
P304
P356
10.1373/CLINCHEM.2013.209965
P407
P577
2013-09-06T00:00:00Z